凯普生物
(300639)
| 流通市值：37.86亿 | | | 总市值：38.53亿 |
| 流通股本：6.35亿 | | | 总股本：6.47亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 314,993,117.77 | 134,063,936.62 | 815,528,791.93 | 610,244,080.75 |
| 营业收入 | 314,993,117.77 | 134,063,936.62 | 815,528,791.93 | 610,244,080.75 |
| 二、营业总成本 | 375,396,099.82 | 170,514,212.19 | 1,006,571,895.71 | 678,692,168.29 |
| 营业成本 | 167,001,818.14 | 68,979,378.3 | 426,724,453.06 | 281,847,046.05 |
| 税金及附加 | 4,236,014.19 | 1,784,073.26 | 11,221,551.23 | 7,599,656.04 |
| 销售费用 | 90,742,288.05 | 34,586,046.3 | 260,803,852.59 | 170,995,014.41 |
| 管理费用 | 101,183,145 | 50,748,593.18 | 221,200,576.6 | 167,456,535.91 |
| 研发费用 | 34,052,944.72 | 16,764,468.2 | 85,637,867.59 | 64,903,343.27 |
| 财务费用 | -21,820,110.28 | -2,348,347.05 | 983,594.64 | -14,109,427.39 |
| 其中:利息费用 | 1,059,827.46 | 530,416.22 | 1,577,452.76 | 1,368,240.45 |
| 其中:利息收入 | 10,290,871.93 | 6,134,475.31 | 22,249,930.08 | 17,946,316.7 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,438,941.3 | -6,421.5 | 4,050,096 | -513.72 |
| 加:投资收益 | 243,383.24 | -489,984.64 | 5,153,928.52 | 8,809,664.9 |
| 资产处置收益 | 358,182.51 | -23,734.85 | -248,851.5 | 1,683,652.36 |
| 资产减值损失(新) | -10,894,159.27 | -374,940.03 | -37,745,728.58 | -21,008,057.79 |
| 信用减值损失(新) | -57,564,018.85 | -4,871,555.05 | -608,006,152.48 | -382,091,593.16 |
| 其他收益 | 2,143,073.8 | 1,013,535.18 | 6,120,564.87 | 4,228,268.28 |
| 四、营业利润 | -121,677,579.32 | -41,203,376.46 | -821,719,246.95 | -456,826,666.67 |
| 加:营业外收入 | 90,302.4 | 62,451.28 | 731,930.32 | 1,021,151.67 |
| 减:营业外支出 | 5,574,138.07 | 3,635,094.93 | 11,980,037.4 | 4,655,808.36 |
| 五、利润总额 | -127,161,414.99 | -44,776,020.11 | -832,967,354.03 | -460,461,323.36 |
| 减:所得税费用 | 9,955,385.37 | -411,246.35 | 117,382,815.76 | -59,742,116.52 |
| 六、净利润 | -137,116,800.36 | -44,364,773.76 | -950,350,169.79 | -400,719,206.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -137,116,800.36 | -44,364,773.76 | -950,350,169.79 | -400,719,206.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -89,591,424.25 | -27,303,972.82 | -654,881,994.73 | -261,923,132.65 |
| 少数股东损益 | -47,525,376.11 | -17,060,800.94 | -295,468,175.06 | -138,796,074.19 |
| 扣除非经常损益后的净利润 | -95,610,389.61 | -24,761,450.61 | -659,734,818.81 | -270,184,869.94 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.14 | -0.04 | -1.02 | -0.41 |
| (二)稀释每股收益 | -0.14 | -0.04 | -1.02 | -0.41 |
| 八、其他综合收益 | -21,365,718.72 | -3,341,950.91 | 4,588,473.21 | -6,565,547.68 |
| 归属于母公司股东的其他综合收益 | -21,365,718.72 | -3,341,950.91 | 4,588,473.21 | -6,565,547.68 |
| 九、综合收益总额 | -158,482,519.08 | -47,706,724.67 | -945,761,696.58 | -407,284,754.52 |
| 归属于母公司股东的综合收益总额 | -110,957,142.97 | -30,645,923.73 | -650,293,521.52 | -268,488,680.33 |
| 归属于少数股东的综合收益总额 | -47,525,376.11 | -17,060,800.94 | -295,468,175.06 | -138,796,074.19 |
| 公告日期 | 2025-08-26 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |